The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | MRD negativity and its role as a predictor for CLL patient responses
John Seymour, MD, MPH from the Peter MacCallum Cancer Center, Melbourne, Australia, discusses the value of minimal residual disease (MRD) negativity in chronic lymphocytic leukemia (CLL) patients as a predictive marker of their quality of response, especially in evaluating the clinical effectiveness of novel agents such as venetoclax and ibrutinib. He notes that the quality of patients’ responses will be particularly important in this era of novel agents for CLL treatment. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
